
Please try another search
By Sam Boughedda
Investing.com -- Caredx Inc (NASDAQ:CDNA) announced Monday evening that the company has won its false advertising case against Natera Inc (NASDAQ:NTRA).
CareDx won $44.9 million in damages. Shares rose 8.8% after the announcement.
The jury determined that Natera intentionally misled the transplant community by engaging in false advertising and promoting its Prospera kidney transplant rejection assessment test.
CareDx was awarded $21.2 million compensatory damages and $23.7 million punitive damages. CareDx said "overwhelming evidence" emerged that Natera's senior executives knew of the unscientific and unreliable statements made to market Prospera.
"The jury found Natera liable for false advertising based on Natera's false comparisons of its kidney transplant assessment test, Prospera, to CareDx's market-leading AlloSure technology," CareDx said in its press release.
Natera stock is down 16%.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.